Companies Abcodia

Detecting ovarian  cancer early


Early detection of cancer is known to increase survival rates. Yet conventional imaging detection is expensive, slow, and inaccurate, and access to the technology is uneven.

ABCODIA is changing that with new biomarker testing procedures that will increase the accuracy of blood tests by observing individual changes over time. It is aiming to develop tests that are more accessible than imaging and more sensitive than existing biomarker approaches, increasing the likelihood that more people’s lives can be saved.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More